Cardiovascular Drugs Practice Questions

Q: Which of the following medications is most commonly associated with bradycardia?

Propranolol (Beta Blocker). ***Propranolol (Beta Blocker)*** - Propranolol is a **non-selective beta-blocker** that blocks both β1 and β2 adrenergic receptors. - By blocking **β1 receptors in the heart**, it directly reduces heart rate (negative chronotropic effect) and is **most commonly associated with bradycardia** among the given options. - Bradycardia is a **predictable and common therapeutic effect** of beta-blockers, occurring even at therapeutic doses. - Beta-blockers are the **classic drug class** taught as causing bradycardia in medical pharmacology. - Other effects include reduced contractility (negative inotropic) and slowed AV conduction. *Digitalis (Digoxin)* - Digoxin inhibits the **Na+/K+ ATPase pump** and increases **vagal tone**, which can slow AV nodal conduction. - While digoxin CAN cause bradycardia, this typically occurs in **toxicity or overdose** rather than as a common therapeutic effect. - At therapeutic doses, digoxin is used for its positive inotropic effect and rate control in atrial fibrillation. - Bradycardia from digoxin is less commonly encountered compared to beta-blockers in routine clinical practice. *Lisinopril (ACE Inhibitor)* - Works by inhibiting **angiotensin-converting enzyme**, causing vasodilation and reducing blood pressure. - Acts on the **renin-angiotensin-aldosterone system** and does not typically affect heart rate. - Not associated with bradycardia. *Amlodipine (Calcium Channel Blocker)* - A **dihydropyridine calcium channel blocker** that primarily causes peripheral vasodilation. - Unlike **non-dihydropyridine CCBs** (verapamil, diltiazem), amlodipine has minimal effect on the **SA and AV nodes**. - May actually cause **reflex tachycardia** due to vasodilation rather than bradycardia.

Q: What is the effect of nicotinic acid on cholesterol levels?

Increases HDL. ***Increases HDL*** - **Nicotinic acid**, or niacin, effectively **raises high-density lipoprotein (HDL)** cholesterol levels, which is beneficial for cardiovascular health. - It achieves this by decreasing the **hepatic uptake of HDL-apoA-I**, thus prolonging the half-life of HDL particles. *Increased triglyceride synthesis* - Nicotinic acid actually **reduces triglyceride synthesis** and secretion by the liver. - It **inhibits diacylglycerol acyltransferase 2 (DGAT2)**, a key enzyme in triglyceride synthesis. *Type II hyperlipoproteinemia* - **Type II hyperlipoproteinemia** is characterized by elevated **LDL cholesterol**. - While nicotinic acid can lower LDL, its primary effect and a key distinguishing feature is its ability to significantly **raise HDL**, not cause hyperlipoproteinemia. *Decreased hydrolysis of VLDL* - Nicotinic acid **enhances the clearance of VLDL** (very-low-density lipoprotein) and IDL (intermediate-density lipoprotein) from plasma. - It **decreases VLDL synthesis and secretion** rather than decreasing its hydrolysis.

Q: Which of the following changes in ECG is most commonly associated with Digitalis use?

Prolonged PR interval. ***Prolonged PR interval*** - Digitalis increases **parasympathetic tone** and slows **AV nodal conduction**, leading to a prolonged PR interval [1], [2]. - This effect is often an expected finding and may indicate therapeutic drug levels rather than toxicity, though significant prolongation can be a sign of overdose [1]. *Tall T waves* - **Tall, peaked T waves** are more commonly associated with **hyperkalemia**, a condition that can be exacerbated by digitalis toxicity but is not a direct ECG effect of digitalis itself [3]. - Digitalis typically causes **flattened or inverted T waves** as part of its characteristic "digitalis effect." *ST segment elevation* - **ST segment elevation** is a hallmark sign of **myocardial ischemia or infarction**, indicating acute coronary events. - While digitalis toxicity can cause arrhythmias, it does not directly lead to ST segment elevation. *Prolonged QT interval* - A **prolonged QT interval** is associated with an increased risk of **torsades de pointes** and is a common side effect of many antiarrhythmic drugs and electrolyte imbalances (e.g., hypokalemia, hypomagnesemia). - Digitalis typically causes **shortening of the QT interval** and can predispose to other forms of arrhythmias [1], [4].

Q: Which drug decreases lipoprotein(a) in the blood?

Nicotinic acid (Niacin). ***Nicotinic acid (Niacin)*** - **Nicotinic acid**, particularly at higher doses, is known to significantly **reduce lipoprotein(a) [Lp(a)] levels** in the blood, although the exact mechanism is not fully understood. - This effect is clinically relevant because elevated Lp(a) is an **independent risk factor for cardiovascular disease**. *Statins* - **Statins** are potent inhibitors of **HMG-CoA reductase**, primarily known for reducing **LDL cholesterol** production. - While they are highly effective in lowering LDL-C, statins generally have **minimal or no effect on Lp(a)** levels, and some studies even suggest a potential slight increase. *Ezetimibe* - **Ezetimibe** works by inhibiting the absorption of **dietary and biliary cholesterol** in the small intestine via the **Niemann-Pick C1-Like 1 (NPC1L1) protein**. - Its primary effect is to **lower LDL cholesterol**, and it has **minimal to no impact on Lp(a) levels**. *CETP inhibitors* - **Cholesteryl ester transfer protein (CETP) inhibitors** (e.g., anacetrapib, evacetrapib) were developed to increase **HDL cholesterol** and decrease LDL cholesterol by inhibiting the transfer of cholesteryl esters from HDL to VLDL/LDL. - While they do affect lipoprotein metabolism significantly, they have been shown to have **inconsistent or modest effects on Lp(a)** levels, and their clinical use has been limited due to safety concerns or lack of clinical benefit.

Q: Which beta blocker contains a d-isomer responsible for its action?

Nebivolol. ***Nebivolol*** - **Nebivolol** is unique among beta-blockers because its **d-isomer (SRRR-nebivolol)** is responsible for its highly selective beta-1 adrenergic receptor antagonism. - The **l-isomer (RSSS-nebivolol)** of nebivolol causes **vasodilation** via nitric oxide release. *Timolol* - **Timolol** is a non-selective beta-blocker that lacks intrinsic sympathomimetic activity and membrane-stabilizing effects. - It exists as a **racemic mixture**, but its beta-blocking activity does not specifically rely on a d-isomer for its primary action. *Esmolol* - **Esmolol** is an ultra-short-acting, cardioselective beta-1 blocker, primarily used intravenously in acute settings due to its rapid metabolism. - Its beta-blocking activity is not attributed to a specific d-isomer; it is a straightforward competitive antagonist. *Propranolol* - **Propranolol** is a non-selective beta-blocker that inhibits both beta-1 and beta-2 adrenergic receptors [1]. - It is often formulated as a **racemic mixture** (a 50:50 mixture of d- and l-isomers), but its beta-blocking effects primarily reside with the l-isomer [1].

Q: Patient with pulmonary fibrosis. Which antiarrhythmic drug is contraindicated?

Amiodarone. Amiodarone - **Amiodarone** is contraindicated in patients with pulmonary fibrosis due to its well-known and potentially severe pulmonary toxicity, which can exacerbate existing lung conditions or induce new ones like **interstitial lung disease**. Dose-related pulmonary toxicity is the most important adverse effect, and potentially fatal pulmonary fibrosis can be observed even at low doses [1]. - Its long half-life means that its toxic effects, including **pulmonary toxicity**, can persist for an extended period even after discontinuation [1], [2]. *Flecainide* - **Flecainide** is a Class IC antiarrhythmic drug primarily associated with cardiac side effects and is generally not contraindicated in patients with pulmonary fibrosis. - Its main risks include **proarrhythmia**, especially in patients with structural heart disease, but not pulmonary issues [3]. *IV ibutilide* - **IV ibutilide** is a Class III antiarrhythmic agent used for rapid conversion of atrial fibrillation/flutter and is not specifically contraindicated in pulmonary fibrosis. - Its primary concern is the risk of **QT prolongation** and **Torsades de Pointes**, rather than pulmonary complications. *Lidocaine* - **Lidocaine** is a Class IB antiarrhythmic typically used for ventricular arrhythmias, especially in the setting of acute myocardial infarction. It is not contraindicated in pulmonary fibrosis. - Its main side effects are **neurological (e.g., seizures, paresthesias)** at higher doses, not pulmonary complications.

Q: Which of the following drugs can be given in patients of primary pulmonary hypertension?

Bosentan. ***Bosentan*** - **Bosentan** is an **endothelin receptor antagonist** that blocks the vasoconstrictive and proliferative effects of endothelin-1, a key mediator in the pathogenesis of **pulmonary hypertension**. - It is an FDA-approved medication specifically used for the treatment of **pulmonary arterial hypertension (PAH)**, improving exercise capacity and delaying clinical worsening. *Icatibant* - **Icatibant** is a **bradykinin B2 receptor antagonist** used in the treatment of **hereditary angioedema**. - It has no known role or efficacy in the management of **primary pulmonary hypertension**. *Labetalol* - **Labetalol** is a **beta-blocker** with **alpha-1 adrenergic blocking activity** used primarily for systemic **hypertension** and **hypertensive emergencies**. - Beta-blockers are generally **contraindicated** in pulmonary hypertension as they can worsen right heart function and lead to clinical deterioration. *Sodium nitroprusside* - **Sodium nitroprusside** is a **direct arterial and venous vasodilator** used in hypertensive crises and severe heart failure by reducing both preload and afterload. - While it can lower systemic blood pressure, its use in pulmonary hypertension is **limited** due to the risk of **systemic hypotension** and the lack of selective pulmonary vasodilation compared to other agents.

Q: What is the drug of choice for treating tachycardia induced by digitalis?

Phenytoin. ***Phenytoin*** - Phenytoin is the traditional drug of choice for **digitalis-induced tachyarrhythmias** as it blocks **sodium channels**, suppresses **automaticity**, and uniquely improves **AV conduction**. - It effectively counteracts digitalis toxicity by stabilizing the **cardiac membrane** and reducing **ectopic ventricular beats** without worsening conduction abnormalities. *Lidocaine* - Though lidocaine is a **Class IB antiarrhythmic** effective for ventricular arrhythmias, it was not the standard answer for this exam question context. - In modern practice, lidocaine may be preferred due to better **safety profile** and **IV availability**, but phenytoin remains the textbook answer for digitalis toxicity. *Reducing the dosage of digoxin* - While reducing digoxin dosage is important in **chronic management** of digitalis toxicity, it does not provide immediate relief from life-threatening arrhythmias. - This approach is too slow for acute situations requiring prompt **pharmacological intervention** to control dangerous tachycardia. *Verapamil* - Verapamil is **contraindicated** in digitalis toxicity as it can worsen **AV block** and exacerbate the **bradycardia** often associated with digitalis intoxication. - It can also increase **digoxin serum levels** by reducing renal clearance, potentially worsening the toxicity rather than treating it.

Q: What type of drug is Sacubitril?

Neutral endopeptidase inhibitor. ***Neutral endopeptidase inhibitor*** - **Sacubitril** is specifically a **neprilysin inhibitor**, which is a type of neutral endopeptidase. - It works by preventing the breakdown of **natriuretic peptides**, leading to vasodilation and natriuresis, beneficial in heart failure. *ACE inhibitor* - **ACE inhibitors** block the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced aldosterone. - While sacubitril is often given in combination with an **angiotensin receptor blocker (valsartan)**, it is not an ACE inhibitor itself. *Calcium channel inhibitor* - **Calcium channel inhibitors** block the influx of calcium into vascular smooth muscle cells and cardiac myocytes, causing vasodilation and reduced myocardial contractility. - This is a distinct mechanism of action from sacubitril, which affects peptide degradation. *Beta adrenergic blocker* - **Beta-adrenergic blockers** inhibit the effects of catecholamines on beta-adrenergic receptors, reducing heart rate and myocardial contractility. - They are used in various cardiovascular conditions but operate through a different pathway than sacubitril.

Question 1

Which of the following medications is most commonly associated with bradycardia?

Accepted Answer

Propranolol (Beta Blocker)

Answer

Lisinopril (ACE Inhibitor)

Answer

Amlodipine (Calcium Channel Blocker)

Answer

Digitalis (Digoxin)

Question 2

What is the effect of nicotinic acid on cholesterol levels?

Accepted Answer

Increases HDL

Answer

Increased triglyceride synthesis

Answer

Type II hyperlipoproteinemia

Answer

Decreased hydrolysis of VLDL

Question 3

Which of the following changes in ECG is most commonly associated with Digitalis use?

Accepted Answer

Prolonged PR interval

Answer

Tall T waves

Answer

ST segment elevation

Answer

Prolonged QT interval

Question 4

Which drug decreases lipoprotein(a) in the blood?

Accepted Answer

Nicotinic acid (Niacin)

Answer

Statins

Answer

Ezetimibe

Answer

CETP inhibitors

Question 5

Which beta blocker contains a d-isomer responsible for its action?

Accepted Answer

Nebivolol

Answer

Timolol

Answer

Esmolol

Answer

Propranolol

Question 6

Patient with pulmonary fibrosis. Which antiarrhythmic drug is contraindicated?

Accepted Answer

Amiodarone

Answer

Flecainide

Answer

Lidocaine

Answer

IV ibutilide

Question 7

What is the primary mechanism of action of beta-blockers in the management of hypertension?

Accepted Answer

Decreasing heart rate and contractility to reduce cardiac output.

Answer

Direct relaxation of vascular smooth muscle.

Answer

Vasodilation through alpha-adrenergic blockade.

Answer

Inhibition of the renin-angiotensin-aldosterone system (RAAS).

Question 8

Which of the following drugs can be given in patients of primary pulmonary hypertension?

Accepted Answer

Bosentan

Answer

Icatibant

Answer

Sodium nitroprusside

Answer

Labetalol

Question 9

What is the drug of choice for treating tachycardia induced by digitalis?

Accepted Answer

Phenytoin

Answer

Lidocaine

Answer

Reducing the dosage of digoxin

Answer

Verapamil

Question 10

What type of drug is Sacubitril?

Accepted Answer

Neutral endopeptidase inhibitor

Answer

ACE inhibitor

Answer

Calcium channel inhibitor

Answer

Beta adrenergic blocker

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?